Senses Disorder TRIZ Cases

Site-directed mutations in the Tie2 ectodomain create Ang2 selectivity, preserving Ang1 protective functions while inhibiting inflammation.

Acylsulfonamide prodrugs hydrolyze to reveal acidic moieties, selectively eliminating senescent cells while sparing healthy tissue.

Segmented mini-tablet implants distribute pharmaceutical payloads to prevent dose dumping while maintaining therapeutic blood plasma levels.

AAV vectors deliver ARSB to the cornea, overcoming blood-eye barriers that block systemic enzyme replacement therapy.

Optimized complementarity-determining region sequences enhance neutralizing activity and specificity of anti-human interleukin-33 antibodies.

Asymmetric sd-rxRNAs combine double-stranded recognition with single-stranded hydrophobic conjugates to enable efficient cellular uptake in retinal tissues.

Long chain fatty alcohol modifier prevents burst release of water-soluble therapeutic agents from biodegradable polymeric carriers, maintaining linear kinetics.

Norrin restores VE-cadherin and claudin-5 expression to repair compromised inter-cellular junctions, reducing fluid accumulation in retinal edema.

A specialized copolymer eye drop formulation enhances lacrimal fluid volume and mucin levels on the corneal surface.

Differentiating stem cells into macular or peripheral retinal pigment epithelial cells using specific chemical cues.

Peptide ligands enable targeted delivery to photoreceptors and RPE cells, replacing risky viral vector injections.

Small molecule tetrahydroimidazopyridine derivatives inhibit tumor necrosis factor alpha activity through specific molecular binding mechanisms.

Saturated oils and low-concentration cetalkonium chloride maintain chemical stability while minimizing eye irritation from high surfactant levels.

Heteroaryl compounds trap all-trans retinaldehyde, preventing A2E accumulation while extending pharmacological half-life to treat macular degeneration.

A fully human monoclonal antibody binds interleukin-25 with high affinity to block signaling pathways.

Engineered MREG protein degrades lipofuscin accumulation in photoreceptor cells, stabilizing retinal health against Stargardt disease progression.

Strontium alginate hydrogels suppress cell division to maintain viability during ambient transport, eliminating refrigeration costs.

2,5-dihydroxybenzene derivatives inhibit cell proliferation and induce apoptosis to treat psoriasis.

Chimeric proteins combine PilA and P5 antigens to elicit specific B-cell and T-cell immune responses against Haemophilus influenzae.

An MCT inhibitor composition targets macrophages to reduce pathological VEGF secretion while preserving normal retinal function.

Round window membrane delivery bypasses direct injection, preserving endocochlear potential while enabling gene transfer.

A dual-release pharmaceutical composition combines fat-soluble quercetin with water-soluble Perilla frutescens extract to enhance gastrointestinal absorption.

Solvent extraction and crystallization purify cannabinoids to 95% purity without chromatography, reducing process complexity.

Cyclodextrin inclusion complexes solubilize poorly water-soluble bilastine in aqueous mometasone formulations, enabling effective nasal administration.

Chiral hydroxamic acid derivatives achieve selective histone deacetylase inhibition while reducing off-target side effects.

Separating mannose 6-phosphate analogues via a specific linker reduces steric hindrance and increases CI-M6PR binding affinity.

Segmented antibody fragments reduce molecular size and immune risks while maintaining binding affinity.

Small molecule inhibitors block Grp94 recognition of mutant myocilin, activating alternative autophagic degradation to reduce toxic accumulation.

Ac-TMP-2 protein derived from hookworms reduces inflammation in mammalian subjects.

Administering OA1 receptor agonists stimulates the signaling pathway to upregulate pigment epithelium-derived factor expression in retinal tissue.

GalNAc4S-6ST siRNA inhibits tissue fibrogenesis by suppressing sulfation at position 4 or 6 of GalNAc sugar chains.

Vegetable-derived fermentation medium with optimized salt and glucose levels produces highly purified collagenase I and II.

A collagen type I carrier extends the antiangiogenic activity cycle of a 34-mer PEDF peptide, addressing frequent injection requirements.

Targeting channelrhodopsin to retinal ganglion cell compartments restores light sensitivity.

Local quality and parameter changes resolve the contradiction between therapeutic efficacy and isoform selectivity in PDE1 inhibitors.

A fusion protein binds E3 ubiquitin ligases to stabilize Wnt receptors.

Targeted nanoparticles reduce off-target effects and improve compliance by delivering anti-VEGF agents locally.

Lanosterol formulations restore lens transparency by inhibiting crystallin protein aggregation in cataract treatment.

Flow cytometry isolates ABCB5-positive stem cells to restore corneal and retinal health where conventional therapies lack regenerative capability.

PEG-PLA diblock copolymers conjugate hydrophobic MetAP-2 inhibitors to resolve poor water solubility and low oral absorption.

CRISPR-Cas9 genome editing eliminates mutant MYOC production to resolve intraocular pressure and patient compliance trade-offs.

Multifunctional compounds integrate monoamine oxidase inhibition, cholinesterase inhibition, and free radical scavenging into a single molecular structure.

Hydrophobic interaction chromatography separates antibody molecules by surface hydrophobicity differences for precise quantitation.

Triazolopyrimidinone derivatives inhibit ferrochelatase to disrupt heme biosynthesis.

Identifying upregulated NTHi genes allows targeted vaccine development that avoids antibiotic resistance and invasive surgery.

Thymol and carvacrol induce autophagy to reverse organ dysfunction in critically ill patients.